The locus encoding human leukocyte antigen (HLA) molecules is highly polymorphic, which enables HLA molecules to present a broad array of peptide antigens, an essential requirement for protective immunity. Conversely, certain HLA allotypes are often associated with aberrant T cell reactivity, including autoimmunity and food-and druglinked hypersensitivity [1] [2] [3] . Humans also have an array of monomorphic antigen-presenting molecules that have distinct and specialized roles in immunity 4 : the CD1 family is well suited to bind lipid-based antigens 5 , while the MHC-class-I-related molecule MR1 presents microbial products associated with vitamin-B2 synthesis for recognition by MAIT cells 6 . Whether MR1 or CD1 can present small-molecule drugs or drug-like molecules to induce an immune response remains unclear.
The locus encoding human leukocyte antigen (HLA) molecules is highly polymorphic, which enables HLA molecules to present a broad array of peptide antigens, an essential requirement for protective immunity. Conversely, certain HLA allotypes are often associated with aberrant T cell reactivity, including autoimmunity and food-and druglinked hypersensitivity [1] [2] [3] . Humans also have an array of monomorphic antigen-presenting molecules that have distinct and specialized roles in immunity 4 : the CD1 family is well suited to bind lipid-based antigens 5 , while the MHC-class-I-related molecule MR1 presents microbial products associated with vitamin-B2 synthesis for recognition by MAIT cells 6 . Whether MR1 or CD1 can present small-molecule drugs or drug-like molecules to induce an immune response remains unclear.
MAIT cells are an evolutionary conserved subset of innate-like T cells found in many mammals 7, 8 . Although the function of MAIT cells is emerging, they are considered to have key roles in immunity [9] [10] [11] . MAIT cells are abundant in humans, representing up to 10% of the total T cell population in the blood 12 . MAIT cells mostly express a TCR with an 'invariant' TCR α-chain (TRAV1-2 recombined with TRAJ33, TRAJ20 or TRAJ12) paired with a limited array of TCR β-chains 8, 13, 14 . MR1 molecules can present stimulatory pyrimidines and non-stimulatory pyrimidine analogs associated with vitamin B2 and vitamin B9, respectively, for surveillance by MAIT cells. For example, some uracils and lumazines derived from riboflavin biosynthesis activate MAIT cells, whereas derivatives of folic acid, including 6-formylpterin (6-FP), are non-stimulatory ligands 15, 16 . A key difference between those stimulatory antigens and non-stimulatory antigens is that the former have a ribityl chain that mediates contacts with the TCR on the MAIT cell (the 'MAIT TCR') 17 . After being activated via their TCRs, MAIT cells rapidly secrete an array of pro-inflammatory cytokines, proliferate and have the ability to kill bacterially infected cells 18, 19 . It is therefore important to understand the range of ligands that can modulate MAIT cell function.
Through the use of in silico discovery approaches, we have identified potential MR1-binding ligands, including some commonly prescribed drugs and drug-like molecules. Furthermore, we evaluated these ligands for their ability to modulate MAIT cell function through their interaction with MR1. We found that some ligands caused upregulation of MR1 expression on the cell surface and inhibited the activation of MAIT cells, while others activated MAIT cells. Consequently, we demonstrate that MR1 can capture chemically diverse scaffolds. These observations indicate that some drugs and drug-like molecules affect MAIT cell function.
RESULTS

In silico prospecting for MR1 ligands
Published studies have identified uracil analogs, including 5-(2-oxopropylideneamino)-6-d-ribitylaminouracil (5-OP-RU), and pterin or pteridine analogs (such as 6-FP) as agonists and inhibitors, respectively, of the activation of MAIT cells 15 . These compounds contain simple pyrimidine heterocycles as scaffolds, which suggests that the ligand-binding site of MR1 (the A′-pocket) has a propensity to bind small molecules, possibly including drugs, drug-like molecules or fragments 16 .
To identify other chemical scaffolds able to bind to MR1, we conducted multiple in silico screens in parallel using various chemical libraries, including 6,000 in-house organic compounds and 1,216 drugs (approved by the US Food and Drug Administration (FDA)) from the Distributed Structure-Searchable Toxicity database to target the A′-pocket (Fig. 1) . On the basis of binding to MR1 by the most active known MAIT cell antigen (5-OP-RU), we performed fragment-based virtual screening of the 6,000-compound library to identify small aromatic aldehydes or carboxylates that might neutralize the charge of the important Schiff-base-forming Lys43 residue of MR1, as well as to identify simple pyrimidines, quinones and enones (Fig. 1a) , to occupy the same site of MR1 to which 5-OP-RU binds (Fig. 1b) . This led to 147 hits, including those presented here (Fig. 1c) . Additionally, a database of 1,216 FDA-approved drugs was screened in silico ( Fig. 1d) for (d) Shape-based in silico virtual matching (with ROCS and Maestro software) of a pool of drugs (top) to 6-FP as a structural template, followed by visual examination of the 100 top-ranked drugs (ranked on the basis of shape similarity) to determine the extent to which they matched the shape of 6-FP. (e) Superimposition of the drugs identified in d onto the shape of 6-FP. (f) Examples of drugs identified as virtual hits from the shape-based screen in d; colors correspond to those of the superimposed structures in e. (g) Receptor-based virtual screen for the identification of drug hits as putative MR1-binding ligands, beginning with pre-filtering of drugs on the basis of molecular weight (MW) (top), followed by screening in silico for predicted binding with the GOLD and GLIDE programs, then ranking with the ChemPLP, Chemscore and ASPscore scoring functions of GOLD, as well as assignment of scores by GLIDE Score, followed by visual examination of the 200 top-scoring drugs for their docked poses within the MR1 binding site. (h) Docked poses of 20 virtual hits (cyan) from a subset of the pre-filtered drug database in g in the putative ligandbinding site in MR1 defined by key protein residues (yellow sticks). (i) Examples of virtual hits from the receptor-based virtual screen in g.
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VOLUME 18 NUMBER 4 APRIL 2017 nature immunology A r t i c l e s shapes that matched those of the ligands 6-FP (Fig. 1e) and 5-OP-RU ( Supplementary Fig. 1a) ; this led to 16 'virtual hits' , including those presented here (Fig. 1f) . A third in silico approach involved receptorbased virtual docking (Fig. 1g ) of a subset of 470 of the 1,216 FDAapproved drugs (molecular size, 150-300 Da) into the ternary crystal structure of 5-OP-RU bound to a complex of MR1 and a MAIT TCR ( Fig. 1h and Supplementary Fig. 1b) . This led to identification of 20 virtual hits, including those presented here (Fig. 1i) . In summary, these parallel approaches (Fig. 1) produced 183 distinct hits with chemically diverse structures (Supplementary Tables 1 and 2) , among which 22 were identified as previously unknown modulators of the MR1-MAIT cell axis ( Supplementary Fig. 1c) ; this suggested that MR1 has the potential to bind to many structurally different compounds. Supplementary Table 3 and Supplementary Figs. 1c and 2a) . Of the sixteen compounds that upregulated MR1 expression, eight were agonists ( Fig. 2a and Supplementary Fig. 2a) . Thus, although MR1 was able to bind diverse chemical ligands ( Supplementary Fig. 1c) , the requirements related to the activation of MAIT cells were more stringent. Notably, many of the aromatic aldehydes, ketones or carboxylic acids that fit into MR1 (Fig. 1a and Supplementary Tables 1-3) did not upregulate the cell-surface expression of MR1 appreciably (Fig. 2a, Supplementary Table 3 and Supplementary Figs. 1c  and 2a) , which indicated that simply neutralizing the charge of Lys43 (MR1) through either Schiff-base formation or an ionic interaction was insufficient for binding to MR1.
We then compared the MR1-binding and inhibitory ability of 6-FP and acetyl-6-formylpterin (Ac-6-FP) with that of a selection of the compounds that strongly upregulated MR1 expression but were not agonists. These included 3-formylsalicylic acid (3-F-SA), 5-formylsalicylic acid (5-F-SA) and 2-hydroxy-1-naphthaldehyde (2-OH-1-NA) (Fig. 2b) . The kinetics and extent of upregulation of MR1 expression of these three compounds were similar to those of 6-FP ( Fig. 2c and Supplementary Fig. 2b ). 3-F-SA and 2-OH-1-NA also effectively inhibited the activation of MAIT cells in the presence of 5-OP-RU in a dose-dependent manner, as determined by measurement of expression of the activation marker CD69 on three Jurkat cell lines expressing MAIT TCRs: Jurkat.MAIT-A-F7 cells (defined above), Jurkat.MAIT-#6 cells (expressing a TCR that uses TRBV6-4) and Jurkat.MAIT-C-F7 cells (expressing a TCR that uses TRBV20) ( Fig. 2d and Supplementary Fig. 2c ). As determined by the half-maximum inhibitory concentration across the range of 5-OP-RU doses tested, we established that Ac-6-FP was the most potent inhibitor, followed by 3-F-SA and 6-FP, which were comparable in their ability to inhibit the activation of MAIT cells, with 2-OH-1-NA being the least potent inhibitor (Supplementary Table 4) . A similar pattern was observed for production of the cytokine IL-2 (as a marker of activation) by a mouse BW58 cell line transduced to express a MAIT TCR (BW58.CD3.MAIT-Vβ8.2 cells) when those cells were incubated with a mouse M12.C3 B lymphocyte cell line transduced with mouse MR1, as an antigen-presenting cell ( Fig. 2e and Supplementary Table 4) . Upregulation of CD69 expression or IL-2 production by the T cell lines in response to stimulation with phorbol-12-myristate-13-acetate plus ionomycin was not impaired in the presence of these inhibitors ( Supplementary Fig. 2c,d) ; similarly, stimulation of a conventional T cell line by its cognate antigen was not impaired (Supplementary Fig. 2e ), which indicated that the inhibitory effects were specific to the MR1-MAIT cell axis.
The fine specificity underpinning the activation and inhibition of Jurkat cells expressing MAIT TCRs by chemically similar structures was evident in a comparison of 3-F-SA and 5-F-SA. Although 3-F-SA did not stimulate any of the three MAIT-TCR-expressing Jurkat cell lines, 5-F-SA showed modest activation of Jurkat.MAIT-#6 cells that was blocked by a monoclonal antibody (26.5) to MR1, but 5-F-SA did not activate Jurkat.MAIT-A-F7 cells (Fig. 2f) or Jurkat.MAIT-C-F7 cells (data not shown). This indicated that the use of TCR β-chains by MAIT cells was able to 'fine tune' the responsiveness to certain ligands.
Binding and upregulation of MR1 by a drug degradation product The folic-acid derivatives aminopterin and methotrexate have been used to treat certain cancers and autoimmune disorders, including rheumatoid arthritis and psoriasis 20 . Aminopterin readily photodegrades in ultraviolet light to form 2,4-diamino-6-formylpteridine (2,4-DA-6-FP). Although methotrexate is more stable, it nevertheless forms the same photodegradation product 21 . Given the similarity between the naturally occurring photodegradation products 6-FP and 2,4-DA-6-FP (Supplementary Fig. 3a) , we reasoned that 2,4-DA-6-FP might also upregulate the cell-surface expression of MR1. Indeed, photodegradation preparations of aminopterin supported the refolding of MR1 and upregulated the cell-surface expression of MR1, whereas untreated aminopterin did not ( Supplementary Fig. 3b-d) .
Mass spectrometry comparing the captured antigen with the synthetically produced compound showed that 2,4-DA-6-FP was captured within the refolded MR1 molecule (Supplementary Fig. 3e) . Collectively, these studies identified the metabolite 2,4-DA-6-FP as a previously undescribed ligand of MR1.
Activation of MAIT cells by diclofenac metabolites
We also characterized an agonist drug identified by the functional screen: diclofenac (DCF). Although it did not apparently upregulate cell-surface expression of MR1, DCF activated Jurkat.MAIT-A-F7 cells, with this activation being blocked by the monoclonal antibody 26.5 to MR1 and competitively inhibited by Ac-6-FP in a dosedependent manner (Fig. 3a) . The level of stimulation by DCF at a ligand concentration of 100 µM was greater than that of the ribityllumazine agonists, 6,7-dimethyl-8-D-ribityllumazine (RL-6,7-DiMe) and 7-hydroxy-6-methyl-8-D-ribityllumazine (RL-6-Me-7-OH) 16 and was comparable to maximum stimulation with 5-OP-RU, albeit with 5-OP-RU at a much lower concentration (Fig. 3a) . Although DCF activated Jurkat.MAIT-A-F7 cells, which express a TCR that uses TRBV6-1, it did not activate the two other cell lines, Jurkat.MAIT-#6, and Jurkat.MAIT-C-F7, which express TCRs that use TRBV6-4 or TRBV20, respectively (Fig. 3b) ; this indicated that the agonistic properties of DCF were dependent on the TCR β-chain segment used, A r t i c l e s suggestive of activation specific to the subset of MAIT cell. Moreover, the activation of Jurkat.MAIT-A-F7 cells by 5-OP-RU was increased in the presence of DCF, and DCF did not inhibit the activation of Jurkat. MAIT-#6 cells or Jurkat.MAIT-C-F7 cells by 5-OP-RU (Fig. 3c) .
To determine if DCF was broadly stimulatory to MAIT cells, we tested a panel of 12 cell lines that express MR1-restricted TCRs 13, 22 that varied in their use of TCR α-and β-chains, as well as in their reactivity to 5-OP-RU, 6-FP, Ac-6-FP and an absence of ligand, by assessing their reactivity to DCF in the presence of C1R.MR1 cells ( Fig. 3d and Supplementary Fig. 4a,b) . Given that DCF is known to be metabolized, we determined whether the observed stimulation was due to DCF itself or to any (or all) three of its hydroxyl metabolites Ac-6-FP 26.5 
(4′-hydroxy DCF (4′-OH-DCF), 5-hydroxy DCF (5-OH-DCF) and 4′,5-dihydroxy DCF (4′,5-diOH-DCF)) and two glucuronide conjugates (DCF acyl-β-d-glucuronide and DCF acyl-β-d-glucuronide allyl ester) (Fig. 3e) . DCF and its metabolites did not modulate the stimulation of a conventional T cell line by its cognate antigen ( Supplementary Fig. 4b ), which ensured the specificity of the responses observed. Of the cell lines tested, the Jurkat.MAIT-A-F7 cell line (and thus the A-F7 TCR) was specifically stimulated by DCF; indeed, for this cell line, stimulation by 5-OH-DCF was stronger than stimulation by DCF itself (Fig. 3d,e) . Similarly, another 10 of the 12 cell lines tested responded modestly to 4′-OH-DCF, whereas none of the other DCF metabolites yielded specifically increased responses (Fig. 3d,e and Supplementary Fig. 4a,b) . Collectively, these results indicated that the observed activation of a MAIT cell line by DCF might be more attributable to one of its metabolites.
Presentation of drugs and drug-like molecules by MR1
Given that many drugs are metabolized within cells, we next sought to determine whether some of the compounds that inhibited or activated MAIT cells had been metabolized in antigen-presenting cells before being presented by MR1 at the cell surface. To investigate this, we immunoprecipitated MR1 from the surface of C1R.MR1 cells and used mass spectrometry to analyze the ligands captured by MR1. To validate this approach, we incubated C1R.MR1 cells with Ac-6-FP and specifically detected this ligand in the MR1 eluate fraction (Fig. 3f) .
Using this approach, we also determined that 3-F-SA was presented by MR1 on the cell surface (Fig. 3f) . Next, we established that it was DCF metabolites, not DCF itself, that were presented on the cell surface: the metabolites of DCF that bound to MR1 on the cell surface included hydroxylated DCF (either 5-OH-DCF or 4′-OH-DCF (which are indistinguishable via mass spectrometry), or a combination of the two) and 4′,5-diOH-DCF, a result subsequently confirmed by mass spectrometry of the pure, chemically synthesized DCF metabolites (Fig. 3f) . DCF and the glucuronated species were not detected (data not shown), which could have been due to cell-type-specific metabolism or the larger size of glucuronated DCF that no longer fits the ligand-binding pocket of MR1. Thus, drugs and drug-like molecules, as well as their metabolites, were presented by MR1 to MAIT cells.
Ex vivo modulation of the activity of MAIT cells
Next we established the extent to which three of those newly identified MR1 ligands (3-F-SA, 5-F-SA and 2-OH-1-NA, and the controls 6-FP and Ac-6-FP) were able to modulate the activity of MAIT cells ex vivo. We obtained peripheral blood mononuclear cells from five donors and identified MAIT cells as TRAV1-2 + lymphocytes positive for the MR1-5-OP-RU tetramer, among the CD3 + population of cells. We then assessed competitive inhibition by the drugs and druglike molecules of the 5-OP-RU-dependent activation of the MAIT cells, assaying production of the inflammatory cytokines TNF and IFN-γ as activation markers. The compounds inhibited the activation of MAIT cells in a dose-dependent manner, with Ac-6-FP as the most potent competitive inhibitor, followed by 3-F-SA (Fig. 4a) . Less-potent inhibitory effects were observed for 2-OH-1-NA, 5-F-SA and 6-FP (Fig. 4a) . We also assessed the ability of these compounds to inhibit the proliferation of MAIT cells when incubated with 5-OP-RU. The pattern of inhibitory effects on cytokine production mirrored A r t i c l e s the inhibitory effects on cell proliferation (Fig. 4b) . MAIT cells and TRAV1-2 + cells negative for the MR1-5-OP-RU tetramer (non-MAIT cells) produced cytokines in response to stimulation with phorbol-12-myristate-13-acetate plus ionomycin (Supplementary Fig. 5a ) and proliferated in response to plate-bound antibody to the TCR invariant chain CD3 (anti-CD3) and antibody to the costimulatory receptor CD28 (anti-CD28) (Supplementary Fig. 5b) , regardless of the presence of inhibitory molecules, which indicated that toxicity was unlikely to have stimulated inhibition. Thus, drugs and drug-like molecules affected the activity of MAIT cells ex vivo.
In vivo modulation of the activity of MAIT cells
We next established the efficacy of two of those ligands in inhibiting the proliferation of MAIT cells in vivo; for this, we used a previously established MAIT cell model in C57BL/6 mice 23 . In this model, synthetic 5-OP-RU in conjunction with stimulation via Toll-like receptors (TLRs) causes MAIT cells to accumulate in the lungs to make up to about 25-50% of αβ T cells, compared with their abundance of 0.5-2% in the lungs of naive mice. TLR stimulation can be provided either by synthetic TLR agonists such as the synthetic lipopeptide Pam 2 Cys (which triggers TLR2 and TLR6) 24 , the synthetic RNA duplex poly(I: C) (which triggers TLR3) or CpG dinucleotides (which trigger TLR9) or by bacteria deficient in the riboflavin pathway, as we demonstrated for the live attenuated vaccine strain of Salmonella enterica serovar Typhimurium (S. Typhimurium BRD509) that is deficient in riboflavin synthesis (Salm.BRD509∆ribDH) (data not shown).
In a model mimicking infection, in which 5-OP-RU is supplied extracellularly for antigen presentation in conjunction with stimulation of the TLRs by the intracellular bacteria Salm.BRD509∆ribDH, repeated application of Ac-6-FP or 3-F-SA inhibited the accumulation of MAIT cells in the lungs in a dose-dependent manner (Fig. 4c) . Notably Ac-6-FP or 3-F-SA had no effect on the abundance of bacterial colony-forming units, the absolute number of non-MAIT αβ T cells or IL-17 production by non-MAIT αβ T cells in the lungs in response to Salm.BRD509∆ribDH (Supplementary Fig. 6a,b) , which indicated that the inhibitory effects were not due to toxic effects of the inhibitors on the bacteria or T cells. Thus, these inhibitors were able to effectively abolish the activation of MAIT cells in vivo.
Structures of MAIT TCR-MR1-ligand complexes
Next we determined the crystal structures for the A-F7 MAIT TCR (which uses TRBV6-1) bound to MR1 presenting non-stimulatory ligands (2,4-DA-6-FP, 2-hydroxy-5-methoxybenzaldehyde (HMB), 2-OH-1-NA and 3-F-SA) and two activating ligands (DCF and 5-OH-DCF) (Supplementary Table 5 ). All drugs and drug-related compounds were clearly visible within the antigen-binding cleft of MR1 (Fig. 5a-f) . The MAIT TCR docked atop the six MR1-drug or MR1-drug-like compound complexes with very similar topology (Fig. 5g,  Supplementary Fig. 7a-h and Supplementary Table 6) . Thus, the recognition of diverse chemical scaffolds did not translate into diverse docking of the MAIT TCR on MR1. Further, all of the drugs and druglike molecules were located within the A′-pocket of MR1 (Figs. 5-7) , which not only validated the results of the in silico approaches (Fig. 1) but formally demonstrated that this pocket was sufficiently versatile to accommodate distinct chemical identities. Furthermore, the highresolution structural information allowed thorough examination of the amino acids in MR1 that were responsible for ligand capture. All of these non-stimulatory ligands formed a Schiff base with Lys43 at the base of the aromatic cradle and, consistent with their non-stimulatory properties, none of them directly contacted the MAIT TCR (Fig. 6a-e) . 2,4-DA-6-FP was located in a position essentially identical to that of 6-FP, in which the pteridine ring of 2,4-DA-6-FP was sandwiched between Tyr7 and Trp69 and formed additional aromatic pi-interactions with Trp156 and Tyr62 while abutting Ile96 of MR1 (Fig. 6a,b) . The difference between 6-FP and 2,4-DA-6-FP is the presence of a carbonyl group in the former versus an amino group in the latter at position 4 of the pteridine ring. This difference affected the base of the cleft, with either the carbonyl or amino group nestling against Arg9 in the MR1-6-FP complex (Fig. 6a,b) . That last interaction is unfavorable and probably accounted for the weaker upregulation of the cell-surface expression of MR1 (Supplementary Fig. 3b,c) . Thus, subtle chemical differences between ligands were able to affect the associated MR1-binding properties.
The compound 2-OH-1-NA, like 6-FP, has a bicyclic ring structure, and while the planes of the aromatic rings were similarly disposed, 2-OH-1-NA was displaced by ~4Å toward the α1-helix of MR1 (Fig. 6c) . In adopting this binding mode, its 2-hydroxy group, the only polar moiety of 2-OH-1-NA, formed a hydrogen bond to His58 and packed against Trp164 of MR1, while the interactions with Arg9, Arg94 and Trp69 were lost (Fig. 6c) . 3-F-SA and HMB are monocyclic (Fig. 6d,e) ; the latter compound was directly superposable over 2-OH-1-NA and thereby mediated similar interactions with MR1, including the hydrogen bond with His58 ( Fig. 6d-f) . The 5-methoxy group was not involved in polar interactions but was stabilized by packing against Tyr7 of MR1 (Fig. 6d) . In contrast, 3-F-SA was rotated in the same plane by approximately 70° around the Schiff base relative to the positioning of 2-OH-1-NA and, accordingly, was accommodated in a different region of the A′-pocket of MR1 (Fig. 6e) . Specifically, the carboxyl group of 3-F-SA was oriented to form a salt bridge with Arg9 and hydrogen bond to Ser24, while its aromatic ring was wedged between Tyr7 and Trp69 of MR1 (Fig. 6e) . These additional interactions were consistent with the finding that 3-F-SA represented a potent inhibitor of the function of MAIT cells (Fig. 2c) . Thus, there was sufficient plasticity within the A′-pocket of MR1 to accommodate diverse chemical scaffolds.
MAIT TCR-MR1-stimulatory ligand complexes
Comparison of the crystal structures of the MAIT TCR bound to MR1 presenting DCF or 5-OH-DCF provided insight into the agonistic properties of 5-OH-DCF ( Fig. 7 and Supplementary Tables 7  and 8) . Neither species formed a Schiff base with MR1 (Fig. 7d,e) , consistent with the poor ability of DCF (and metabolites thereof) to upregulate MR1 expression (Supplementary Table 3 and data not shown) and reminiscent of results obtained for the weak agonist RL-6-Me-7-OH 17 . Despite that, the positioning of Lys43 remained relatively well fixed within the MR1 cleft, and it formed a hydrogen bond with the adjacent residue His58 (Fig. 7d,e) . In contrast to the non-stimulatory compounds, DCF directly contacted the MAIT TCR (Fig. 7d) . However, the mode for the binding of DCF within the cleft and the subsequent contacts of DCF and MR1 with the MAIT TCR were markedly different from the binding modes and contacts of the MAIT TCR-MR1-5-OP-RU interactions (Fig. 7c-e) . The plane of the central phenylacetic acid ring of DCF was essentially perpendicular to that of 5-OP-RU and all other MR1-ligand complexes (Fig. 7c-f) . Moreover, the dichlorophenyl and phenylacetic acid rings were positioned approximately orthogonal to each other (Fig. 7a) . Here, the dichlorophenyl group was buried toward the base of the cleft, wedged among MR1 residues Tyr7, Tyr62, Trp156 and Trp164 (Fig. 7a) . One of the chloro groups pointed toward Arg94, whereas the other was shielded by Tyr62 and Trp164 and formed a halogen bond with Lys43 (Fig. 7a) . The phenylacetic acid group was sandwiched between Arg9 and Tyr62, with the acetic acid moiety salt-bridging to Arg9 and forming a hydrogen bond with Ser24 of MR1 (Fig. 7a) . Notably, to accommodate the dichlorophenyl ring of DCF within the cleft, MR1 underwent some conformational changes, including a slight reorientation of Tyr7 and, most notably, flipping of Trp69 out of the way to avoid steric clashes with the ligand (Fig. 7c,d) . The reconfiguration of Trp69 had a 'knock-on' effect, in that it caused remodeling of the CDR3β loop of the MAIT TCR, with the TCR residue Glu99β swinging down to salt bridge with MR1 residues Arg9 and Arg94, while Trp96β of the TCR re-orientated to form new contacts with Met72 and Trp69 of MR1 (Fig. 7c,d) . The hydroxyl moiety of Tyr95α from the TCR CDR3α loop had a pivotal role in interacting with the ribityl chain of 5-OP-RU (Fig. 7c) but did not mediate polar interactions with DCF (Fig. 7d) . Instead, the Tyr95α aromatic ring stacked against the phenylacetic acid ring, and the latter also formed van der Waals contacts with Glu99β from the CDR3β loop (Fig. 7d) . The mode of binding of DCF was very similar to that of 5-OH DCF, with one A r t i c l e s notable difference: the 5-OH group of 5-OH-DCF formed a hydrogen bond with Glu99β from the CDR3β loop, and this additional contact to the TCR correlated with its agonist properties and with its ability to stimulate a specific MAIT TCR (Fig. 7e) .
DISCUSSION
A central question in the biology of MAIT cells is whether MR1 is able to present ligands distinct from riboflavin precursors and folic acid-derived metabolites. Here we found that MR1 was able to present a heterogeneous array of organic compounds with diverse chemical scaffolds, including some commonly prescribed therapeutics, that were able to modulate the activity of MAIT cells. Given that pyrimidines are widely used scaffolds in therapeutics, we hypothesized that MR1 might present drugs and drug-like molecules. Indeed, the MR1-binding compounds identified here included a wide range of drugs and drug-like molecules, fragments and derivatives. Our findings also have implications for any future therapy based on the inhibition of MAIT cells, as we demonstrated that administration of MR1-inhibitory ligands affected the function of MAIT cells in an in vivo setting. Our work also suggested that if endogenous ligands have similar chemical scaffolds, they may also affect the function of MAIT cells. Of the ligands that upregulated cell-surface expression of MR1 to detectable levels, all formed a Schiff base with MR1, which emphasizes the importance of forming a covalent adduct 25 . Moreover, the various non-stimulatory ligands adopted different conformations and contacts within the A′-pocket of MR1, which also correlated with differences in their ability to upregulate MR1 expression on the cell surface and inhibit the activation of MAIT cells. Notably, while 3-F-SA was nonstimulatory for the MAIT TCRs tested, 5-F-SA weakly activated a cell line expressing a MAIT TCR. This resonates with the finding that diversity in the MAIT TCR repertoire can permit some folic acid derivatives to stimulate some MR1-restricted T cells and MAIT cells 22 .
Of the drugs tested that activated MAIT cells, DCF showed the greatest potency. Its stimulatory activity was traced to naturally occurring DCF metabolites presented by MR1 on the cell surface. The mode of binding of DCF within the MR1 cleft was distinct from that of other MR1-bound ligands, as it did not form a Schiff base with Lys43, as has also been observed for some ribityllumazines 17 . The 5-OH-DCF metabolite directly contacted the α-and β-chains of the MAIT TCR, which provided insight into both its antigenicity and the ability of the DCF metabolite 4′-OH-DCF to activate specific MAIT TCRs 22 , suggestive of the activation of specific subsets of MAIT cells by DCF metabolites.
A notable consideration is whether the drugs that modulated the activity of MAIT cells manifest clinically important side effects. Although the degree to which methotrexate and aminopterin degrade into 2,4-DA-6-FP in patients is unclear, chemotherapeutic administration of a high dose of methotrexate can result in much higher plasma concentrations of the drug than those required to upregulate MR1 expression on the cell surface 26, 27 . Our results obtained for DCF might potentially reconcile reported immunological complications, such as severe hepatotoxicity. Indeed, DCF was able to activate a MAIT TCR at a concentration that can be achieved in patients after an oral dose 28 . Interestingly, pharmacogenetic studies have revealed that the hepatotoxicity of DCF is much more prevalent in patients with polymorphisms in the enzymes responsible for DCF catabolism, including CYP2C8, which is responsible for conversion of DCF into 5-OH-DCF 29 .
This is the first description, to our knowledge, of drugs affecting the function of MR1, a monomorphic antigen-presenting molecule. Unlike HLA-linked drug hypersensitivities, in which a drug can exert its effect by altering the repertoire of peptides bound by the HLA allomorph 30 32 and Maestro Shape Screen (v 9.4, Schrödinger) were used to search for analogous shapes to 6-FP from 1,216 FDA-approved drugs (FDAMDD_v3b_ 1216_15Feb2008.sdf, from http://www.epa.gov/ncct/dsstox/ DataFiles.html). 2D coordinates of 1,216 drugs were converted to 3D structures with LigPrep (Schrödinger v 9.4). 16 virtual hits were obtained after visual inspection of the top 100 drugs (Combo score, ROCS; shape similarity score, Maestro), three of which were also identified in fragment-based screening (Coumarin, Menadione, and Thioguanine). In addition, Maestro Shape Screen was used to search for analogous shapes to 5-OP-RU from the same drug database (Supplementary Fig. 1a ). In receptor-based structure screening, GOLD (v 5.1) and GLIDE (v 9.4) were used to dock a pre-filtered subset of 470 of 1,216 drugs (150 < MW < 300 Da) into the 5-OP-RU binding site of the MR1-MAIT TCR crystal structure (PDB: 4NQC). Docked ligand poses were scored with ChemPLP, Chemscore and ASPscore in GOLD and with GLIDE. Before the virtual screen, 5-OP-RU was re-docked into MR1 to reproduce its binding pose from the crystal structure and to identify scoring functions best able to predict the crystal pose (data not shown). The structure of MR1 K43A (PDB accession code, 4NQD) was chosen for re-docking 5-OP-RU, as there was no covalent bond to MR1. For the virtual screen, the active site was defined by a 10 Å radius around Arg9 and a rigid MR1 conformation was used for ligand docking. The top scoring 200 drugs were analyzed by visual inspection for ligand-protein interactions simulated from docking. To increase the hit rate, another docking program, GLIDE, was also used in Standard Precision docking mode to score ligand binding using GScore. The active site was the same for GLIDE and GOLD docking. In total 20 drug hits were selected for screening, one of which was also identified via fragment-based screening (Thioguanine).
Aminopterin photodegradation. Aminopterin powder (Sigma-Aldrich) was dissolved in phosphate-buffered saline (pH 8.5) at a concentration of 0.5 mg/ml and exposed to light produced by a 2 × 38W fluorescent lamps at a distance of 40 cm at room temperature. The degree of photodegradation was monitored using the method previously described 33 , whereby the absorbance spectrum was analyzed over 230-480 nm using a PHERAstar plate reader (BMG labtech). The photodegradation reaction was deemed nearly complete after 48 h, which was subsequently confirmed by HPLC analysis against undegraded sample (data not shown). The effect of degraded aminopterin on MR1 surface expression of C1R.MR1 cells was performed as described previously 34 using biotinylated monoclonal antibody (mAb) 26.5 (purified from hybridomas in ref. 41 and biotinylated in-house; dilutions optimized individually) and streptavidin-PE (BD Biosciences). Cells were treated for 3 h before staining, flow cytometry analysis was carried out using a CyAn ADP (Beckman Coulter) and produced data were analyzed using FlowJo v10.1.
Compounds tested in cellular assays in vitro and ex vivo. 6-FP and Ac-6-FP (Schircks Laboratories) were dissolved at 5 mM in water, supplemented with 17 mM NaOH. 5-OP-RU (as 1.52 mM stock solution in DMSO) was used by dilution in PBS to the required concentration immediately before testing (DMSO content was less than 0.01% in final media). All other compounds were obtained commercially (Sigma-Aldrich, Fluka or Sapphire Bioscience) or were synthesized in house and dissolved at 50 mM in DMSO. All compounds were diluted in PBS. For inhibitory compounds, vehicle controls (V) were prepared as follows: V1 of ligands prepared at 5 mM in water supplemented with 17 mM NaOH; V2 of ligands prepared at 50 mM in DMSO.
Cell lines, peripheral blood mononuclear cells (PBMCs) and monocytederived dendritic cells. All cells were cultured in RPMI medium supplemented with 10% FCS and serum complement (RF10 medium). Clonal C1R cells overexpressing MR1 (CIR.MR1) 35 or HLA-B*08:01 (ref. 36) have been described previously and were derived from C1R (ATCC number CRL-1993), a human B lymphoblastoid cell line (LCL). Clonal Jurkat.MAIT cells expressing the TRBV6-1 A-F7 MAIT TCR (Jurkat.MAIT-A-F7), the TRBV6-4 #6 MAIT TCR (Jurkat.MAIT-#6) or the TRBV20 C-F7 MAIT TCR (Jurkat.MAIT-CF7) 15 or the LC13 TCR and CD8αβ (Jurkat.CD8.LC13) 36 . Bulk-sorted SKW-3.M12-64 and SKW-3.M20-64 cells 22 have been described previously and were derived from the human T cell line SKW-3 (DSMZ accession code ACC-53). For the generation of Bw58.CD3.MAIT-V β 8.2 cells, sequential retroviral transduction with genes encoding CD3 and TCR was performed as described previously 38 . In brief, genes encoding fulllength CD3 (CD3 γ-, δ-, ζ-and ε-chains) were designed, purchased and cloned into a self-cleaving 2A-peptide-based (MSCV)-IRES-GFP (pMIG) vector 39 . After sequence verification, mouse-CD3-encoding genes were transduced into the TCR-deficient Bw58 cells. GFP hi cells (Bw58.CD3) were cloned by single-cell flow cytometry. Similarly, genes encoding full-length MAIT TCRs of a V β 8.2 TCR derived from a mouse with transgenic expression of a TCR using the canonical V α 19i segment (V α 19i Cα −/− ) 40 and the endogenous paring TCR β-chain (TRBV13-2*01 (Arden nomenclature V β 8.2), TRBJ2-3*01, CDR3β CASGDAKLGVGAETLYF)) were cloned into pMIG vector and the sequence was verified, and then these were transduced into Bw58.CD3 cells to generate Bw58.CD3.MAIT-Vβ8.2 cells. Similarly bulk sorted Jurkat.76.CD3. AM1, Jurkat.76.CD3.AM2, Jurkat.76.CD3.AM3 and bulk-sorted SKW-3.M33-20 cells were generated based on TCR sequences described previously 22 . For the generation of high-level MR1-expressing antigen-presenting cells (M12. C3.MR1), the same retroviral system was used. M12.C3 cells (an MHC-class-II-deficient B-lymphoblastoid cell line) were transduced with mouse MR1 (pMIG-MR1) and clones were generated by single-cell flow cytometry. PBMCs were isolated from whole blood of healthy donors and stored in liquid nitrogen (authorized by the Australian Red Blood Cross Service Material Supply Agreement with The University of Melbourne) as described previously 13 . Monocyte-derived dendritic cells (mDCs) were generated from PBMCs by incubating plastic-adherent PBMCs for 5 d in RF10 media supplemented with 300 U/ml hGM-CSF (Peprotech) and 100 U/ml hIL-4 (Peprotech). Plasticnon-adherent PBMCs were refrozen in liquid nitrogen and thawed out 1 d before addition to mDCs as autologous lymphocytes in activation assays. T cell lines to produce IL-2, cells were incubated with PMA and ionomycin (final concentration of 10 ng/ml and 1 µg/ml respectively) and the highest concentration of inhibitor. IL-2 production was measured as a mean of T cell activation in ELISA (human: BD Biosciences OptEIA kit, mouse: mAb IL-2 (clone JES6-1A12, BD Biosciences, 1:500) using 100 µl of supernatant, frozen and thawed to kill cells. In brief, IL-2 was assayed with biotinylated mAb to IL-2 and o-Phenylenediamine dihydrochloride (OPD; Sigma-Aldrich) substrate conversion by HRP-Streptavidin detected at 492-nm emission and IL-2 concentrations calculated based on IL-2 standards. For inhibition, inhibiting compounds were added to antigen-presenting cells for 15 min before the addition of 5-OP-RU and T cells. For MR1 blocking, mAb 26.5 (ref. 41) (antibody purified in house from hybridoma provided by T. Hansen (University of Washington) and W.J. Yankelevich (US Food and Drug Administration)) or isotype-matched control mAb (8A5, made in house and specific for the human pre-TCR α-chain) were added at 20 µg/ml for 1 h to antigen-presenting cells before addition of T cells.
Activation of human
To determine the half-maximum inhibition by inhibitory compounds (IC 50 values), background activation levels were subtracted, data normalized, inhibitor concentrations transformed to log and nonlinear regression of log (inhibitor) versus the normalized response determined using Prism software.
All cell lines tested negative for mycoplasma. While SKW-3 cells are listed on the database of cross-contaminated or misidentified cell lines, where they are described as being contaminated with the KE-37 line, we have transfected specific TCR-encoding genes into these cells, which we then recloned and/or enriched by iterative cell sorting for TCR expression. Following these steps the cells were then validated for antigen recognition of cognate antigens in activation experiments.
Detection of upregulation of MR1 on the cell surface. C1R.MR1 cells (1 × 10 5 ) were incubated for various times (Fig. 2c) with vehicle controls, PBS and medium (background), and 100 µM of compounds in 200 µl RF10 medium per well. Then cells were stained with biotinylated mAb 26.5 (anti-MR1) 41 (identified above, dilution 1:1,000) or biotinylated isotype-matched control mAb (8A5; identified above) on ice for 30 min, washed twice with flow cytometry wash, and then stained with Streptavidin-PE (BD Biosciences) and 7AAD (BD Biosciences) on ice for 30 min, washed twice again and fixed by flow cytometry, and data were acquired on a BD LSR Fortessa flow cytometer and analyzed using FlowJo. To allow for comparison between experiments, results relative to background was normalized by setting the % CD69 upregulation by 10 nM 5-OP-RU or % MR1 upregulation by 100 µM 6-FP equal to 100% and results relative to a background of 1 equal to 0%. Compounds that caused activation of Jurkat. MAIT cells and upregulation of MR1 expression greater than 75% at 100 µM and/or 25% at 10 µM compound were considered agonistic and strongly MR1 upregulating, respectively, and those that caused such activation and upregulation greater than 7.5% and less than 75% at 100 µM and/or larger than 7.5% and less than 25% at 10 µM compound were considered weakly agonistic and weakly MR1 upregulating, respectively. For some of the small molecules tested at 100 µM, we observed a toxic effect that resulted in cell death identified by life-dead stain. In these cases, MR1 upregulation was more pronounced at a lower concentration of inhibitor (10 µM) than at 100 µM, for example, 5-hydroxy-1,4-naphtoquinone. Considering MR1 upregulation at 10 µM as part of the selection criteria in such cases thus allowed inclusion of molecules that appeared toxic at 100 µM.
Ex vivo activation of human PBMCs assayed by intracellular cytokine staining. Per sample to mDCs (1 × 10 5 ), PBS (background), vehicle controls and doses of inhibitors were added, followed after 15 min by PBS or titrating amounts of 5-OP-RU. Then autologous lymphocytes (0.5 × 10 6 ) were added per sample. To test if inhibitors affected the ability of cells to produce cytokines, autologous non-plastic-adherent PBMCs were incubated with PMA and ionomycin (final concentrations of 100 ng/ml and 10 µg/ml, respectively) and the highest concentration of inhibitor. Upon incubation for 1 h, brefeldinA (final concentration of 10 µg/ml) was added and incubation continued for 6 h, then surface stained for 20 min at room temperature (Zombie Yellow Fixable Viability Kit, Biolegend, dilution 1:500); anti-CD3-PE-CF594 (clone UCHT1, BD Biosciences, dilution 1:200); anti-TRAV1-2-APC (clone 3C10, Biolegend, dilution 1:50); human MR1-5-OP-RU tetramer, generated as described previously 15 Ex vivo activation of human PBMCs assayed by proliferation. Autologous lymphocytes and mDCs were stained with CellTrace Violet (Molecular Probes) according to the manufacturer's protocol. Per sample to mDCs (1 × 10 5 ), PBS (background), vehicle controls and doses of inhibitors were added, followed after 15 min by PBS or titrating amounts of 5-OP-RU. Then autologous lymphocytes (1 × 10 6 per sample) were added. To test if inhibitors affected the ability of cells to produce cytokines, autologous non-plastic-adherent PBMCs were incubated for 48 h with plate-bound mAb to CD3 (clone OKT3, 10 µg/ml, prepared in-house) plus anti-CD28 (clone L293, BD Biosciences, 2 µg/ml) and the highest concentration of inhibitor in a flat-bottom plate before transfer to a U-shape plate after 48 h. Upon incubation of 5 d, samples were stained for 20 min at room temperature (Zombie Yellow Fixable Viability Kit (Biolegend), dilution 1:500), followed by staining for surface markers as above in the case of intracellular cytokine staining. Samples were washed twice with flow cytometry wash and fixed and data were acquired using a BD LSR Fortessa flow cytometer and analyzed by FlowJo. Percent inhibition was calculated as described above for intracellular cytokine staining.
Mouse in vivo activation or inhibition of the accumulation of MAIT cells in the lungs. Salmonella enterica serovar Typhimurium BRD509 (Salm.BRD509) has been previously described 42 . Salm.BRD509 harbors deletions in aroA and aroD that resulting in limitation of replication and spread of bacteria and has an intact riboflavin synthesis pathway. The BRD509∆ribDH mutant (Salm. BRD509∆ribDH), lacking a gene segment containing ribD and ribH, which encode key enzymes in the riboflavin-synthesis pathway, was constructed by lamda red-recombinase mediated allelic replacement followed by transduction using phage P22 as previously described 15 . BRD509∆ribDH cultures were supplemented with 20 µg/ml riboflavin. Bacteria were cultured at 37 °C statically, in Luria Bertani broth (LB) for 16-18 h to log-phase growth (OD 600 0.6-0.9) in the presence of antibiotics (30 µg/ml streptomycin, 30 µg /ml kanamycin) and riboflavin (20 µg/ml). For the infecting inoculum, bacteria were re-inoculated in pre-warmed medium for a further 2-4 h static culture (OD 600 0.4-0.6). With the estimation that 1 OD 600 = 5 × 10 8 /ml, sufficient bacteria were washed and diluted in PBS for intranasal delivery to C57BL/6 mice. A sample of inoculum was plated onto Luria agar supplemented with antibiotics and riboflavin for verification of bacterial concentration by counting colony-forming units.
Mice were bred and housed in the Biological Research Facility of the Peter Doherty Institute. Male mice 7-8 weeks of age were used in experiments and allocated to separate groups at random (block randomization). The investigators were blinded to the group allocation when assessing the outcome. All procedures were approved by The University of Melbourne Animal Ethics Committee. Mice were intranasally inoculated using a total volume of 50 µl with Ac-6-FP (5 × 10 4 pmol and titrations in PBS plus 1% DMSO) or 3-F-SA (5 × 10 5 pmol and titrations in PBS plus 1% DMSO) at day −2 and day −1 or, alternatively, with vehicle control (PBS plus 1% DMSO). On day 0, mice were inoculated intranasally with BRD509∆ribDH (2 × 10 7 cfu) and 5-OP-RU (3 pmol in PBS of a 14.1 mM stock in DMSO) and/or inhibitory antigens (or vehicle control) in 50 µl per nares. Then, on day 1, day 2 and day 4, mice were inoculated intranasally with 5-OP-RU and/or inhibitor using a total volume of 50 µl. All inoculations were performed on mice anesthetized by isoflurane with an anaesthetizing machine. At day 7, mice were killed by administration of CO 2 and lungs (following heart perfusion with 10 ml cold RPMI) were harvested. To prepare single-cell suspensions, lungs were finely chopped with a scalpel blade and treated with 3 mg/ml collagenase III (Worthington), 1 mg/ml DNase and 2% FCS in RPMI for 90 min at 37 °C with gentle shaking. Cells were then filtered (70 µM) and washed with flow cytometry wash. Red blood cells were lysed from lung preparations with hypotonic buffer TAC (Tris-based Amino Chloride) for 5 min at RT and approximately 1.5 × 10 6 cells were filtered (40 µm) and prepared for staining. To block non-specific staining, cells were incubated with mouse MR1-6-FP tetramer (1:100) diluted in 20 µl of supernatant of hybridoma 2.4G2 (ATCC HB-197) as anti-Fc receptor (2.4G2 hybridoma, grown to a density of 1 × 10 6 to 1.5 × 10 6 cells per ml culture; prepared in-house) for 15 min at RT. Cells were then incubated at RT for 30 min with antibodies (from BD) specific for CD19 (clone 1D3, dilution 1:200), CD45.2 (clone 104, dilution 1:200) and TCRβ (clone H57-597, dilution 1:200), as well as 7AAD (1:500) and mouse MR1-5-OP-RU tetramer 13 , in flow cytometry wash. Cells were fixed with 1% PFA in PBS and 25-to 30-k blank calibration particles (BD) were added to enumerate absolute cell numbers, before analysis on a BD LSR Fortessa flow cytometer.
For intracellular cytokine staining, Golgi Plug (BD Biosciences) was used during all processing steps. Cells stimulated with PMA and ionomycin (20 ng/ml and 1 µg/ml, respectively) for 4h at 37 °C were included as positive controls alongside non-stimulated samples. Surface staining was performed as above, followed by intracellular cytokine staining for IL-17A (clone TC11-18H10, BD Biosciences, dilution 1:200) using the BD Fixation/Permeabilization Kit according to the manufacturer's instructions. Data analysis was performed with FlowJo software.
Generation of soluble proteins for crystallography. Soluble A-F7 MAIT TCR and MR1-β 2 -microglobulin (β 2 m) were folded from inclusion bodies and purified using methods based on those described previously 17 . MR1, β 2 m, TCR α-chain and TCR β-chain were overproduced separately as insoluble inclusion bodies in Escherichia coli BL21(DE3) that had been transformed with pET plasmid containing gene of interest. Protein overproduction was induced in E. coli cells, cultured in LB media that had reached an optical density of 0.5, by the addition a 0.5 µM IPTG, and further culturing for 4 h at 37 °C with shaking. Cells were harvested by centrifugation and lysed by resuspending in 1% (v/v) Triton-X, 4 mM MgCl 2 , 10 mM DTT, 1 g/l lysozyme (Sigma-Aldrich) and 0.5 g/l DNase, and incubating for 2 h at room temperature. Inclusion bodies were harvested from the lysate by centrifugation, before being washed 4 times in 50 mM Tris (pH 8), 0.5% (v/v) Triton-X, 100 mM NaCl and 1 mM EDTA, omitting the Triton-X and NaCl from the final wash step. Lastly, the isolated inclusion bodies were resuspended in 20 mM Tris (pH 8), 6 M guanidinium, 0.5 mM EDTA and 1 mM DTT. The approximate concentration and purity of the isolated inclusion bodies was estimated using SDS-PAGE.
The MAIT TCR was refolded by rapidly diluting 63 mg of α-chain and 42 mg of β-chain as inclusion bodies, into 500 ml of 100 mM Tris (pH 8.5), 2 mM EDTA, 0.4 M l-arginine, 5 M urea 0.5 mM oxidized glutathione, 5 mM reduced glutathione and 1 mM PMSF. Additionally, MR1-β 2 m bound to the compounds, HMB or 3-F-SA was refolded by rapidly diluting 56 mg of MR1 and 26 mg of β 2 m as inclusion bodies, into 400 ml of this same refold buffer described above but with the addition of 5 mg/l of the target compound. For 2,4-DA-6-FP, the refold contained 10 mg/ml of aminopterin that had been photodegraded for 18 h. All refold samples were stirred for 14 h at 4 °C, before dialyzing three times against 15 l of 10 mM Tris (pH 8). Dialysate was passed through Macro-Prep DEAE resin (Bio-Rad) and protein was eluted using 10 mM Tris (pH 8) with 400 mM NaCl. Next, the eluate was concentrated down to 3 ml and purified by size exclusion chromatography using AKTA purification system and a Superdex200 15/60 column (GE Healthcare). Finally, the purified sample was passed over a HiTrap-Q HP (GE Healthcare) and eluted in 10mM Tris (pH8) using a gradient of 0 mM to 300 mM NaCl over 20 CV. Purified protein was assessed for purity using SDS-PAGE and concentrations were calculated from A 280 values measured using a NanoDrop-spectrophotometer (Thermo-fisher).
Crystallization and structure determination. Purified MR1-β 2 m-antigen was mixed with purified MAIT TCR in a 1:1 molar ratio and concentrated to a final concentration of 5 mg/ml. Samples were crystallized by hanging-drop vapor diffusion by mixing protein 1:1 with precipitant consisting of 100 mM BTP (pH 6-6.5), 8-20% (w/v) PEG3350 and 200 mM sodium acetate, as established previously 17 . Crystals formed over 1-5 d at 21 °C. Diffraction data was collected at 100K on the Australian synchrotron MX1 and MX2 beamlines, from crystals that had first been washed in precipitant solution augmented with 10% (v/v) glycerol for cryo-protection. Measured reflections were indexed and integrated using either XDS 43 or imosflm, and scaled and merged using aimless 44 . Phases were calculated by molecular replacement using PHASER 45 , whereby, the MR1 ternary complex, which had the CDR loops and ligand removed, was used as a search model (PDB accession code, 4L4T) 17 . Refinement was performed using phenix.refine 46 , with the initial refinement rounds including simulated annealing, model building was performed with COOT 47 , with MolProbity used in validation 48 . The Grade Web Server was used to generate ligand restraints for all drugs.
For the compounds DCF, 5-OH-DCF and 2-OH-1-NA, which did not refold sufficiently well in vitro (data not shown), a ligand-exchange approach was employed to obtain structures of MR1 presenting these molecules: when 6-FP (data not shown), DCF, 5-OH-DCF or 2-OH-1-NA was added to the MAIT TCR-MR1-antigen protein solution at a concentration of 0.6-2 mM before crystallization, the resulting crystal structures determined from these crystals revealed the added compound at a high occupancy (Fig. 5) . The buried surface area was calculated by the CCP4 implementation of Areaimol and molecular interactions were determined by the CCP4 implementation of CONTACT 44 . All molecular graphics were constructed using PyMOL.
